• Medientyp: E-Artikel
  • Titel: Chilblain-like lesions onset during SARS-CoV-2 infection in a COVID-19-vaccinated adolescent: case report and review of literature
  • Beteiligte: Paparella, Roberto; Tarani, Luigi; Properzi, Enrico; Costantino, Francesco; Saburri, Chiara; Lucibello, Roberta; Richetta, Antonio; Spalice, Alberto; Leonardi, Lucia
  • Erschienen: Springer Science and Business Media LLC, 2022
  • Erschienen in: Italian Journal of Pediatrics
  • Sprache: Englisch
  • DOI: 10.1186/s13052-022-01296-5
  • ISSN: 1824-7288
  • Schlagwörter: General Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>COVID toes or chilblain-like skin lesions have been widely reported during COVID-19 pandemic. Most cases were described in patients with negative microbiological tests for SARS-CoV-2, therefore the possible relationship with SARS-CoV-2 infection, as well as with the nowadays broadly available mRNA-based vaccination, has not been fully elucidated. </jats:p> </jats:sec><jats:sec> <jats:title>Case presentation</jats:title> <jats:p>We here describe the case of a 14-year-old male who developed chilblain-like skin eruptions during SARS-CoV-2 infection despite two mRNA-based vaccine doses and review the clinical and epidemiological characteristics of chilblain-like lesions as a cutaneous presentation of COVID-19 in children.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Most children and adolescent with COVID toes have a mild or asymptomatic SARS-CoV-2 infection. Our report aims to highlight the possible onset of these skin lesions in vaccinated children, if infection has occurred, and the potential use of systemic corticosteroids as a first line treatment. Additional evidence is required to better understand SARS-CoV-2 infection and cutaneous manifestations in children and determine the relationship between chilblain-like lesions and COVID-19 vaccination.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang